MOSUNETUZUMAB

UNII:	LDJ89SS0YG
Formula:
Preferred Substance Name:	MOSUNETUZUMAB

1905409-39-3
BTCT4465A
BTCT-4465A
IMMUNOGLOBULIN G1, HUMANIZED BISPECIFIC, ANTI-(HUMAN CD3 (ANTIGEN))(BTCT4465A .GAMMA.1-CHAIN), DISULFIDE WITH ANTI-(HUMAN CD3 (ANTIGEN)) BTCT4465A .KAPPA.4-CHAIN, ANTI-(HUMAN CD20 (ANTIGEN)) BTCT4465A .GAMMA.3-CHAIN AND ANTI-(HUMAN CD20 (ANTIGEN)) BTCT4465A .KAPPA.1-CHAIN
IMMUNOGLOBULIN G1-KAPPA ANTI-(HOMO SAPIENS T-CELL SURFACE GLYCOPROTEIN CD3 EPSILON CHAIN (CD3E ANTIGEN)) AND IMMUNOGLOBULIN G1-KAPPA ANTI-(HOMO SAPIENS B-LYMPHOCYTE ANTIGEN CD20) HETERODIMERHUMANIZED MONOCLONAL ANTIBODY BISPECIFIC.GAMMA.1 HEAVY CHAIN ANTI-CD3E (1-449) (HUMANIZED VH (HOMO SAPIENS IGHV1-3*01 (83%) (IGHD)-IGHJ4*01) (8.8.12) (1-119) -HOMO SAPIENS IGHG1*01 (CH3(D16>E(358),L18>M(360) ,T26>S(368),L28>A(370),Y67>V(409))) (120-449)) (222-219')-DISULFIDE WITH KAPPA LIGHT CHAIN ANTI-CD3E (1'-219') (HUMANIZED V-KAPPA (HOMO SAPIENS IGKV4-1*01 (92%) IGKJ1*01) (12.3.8) (1'-112') -HOMO SAPIENS IGKC*01 (113'-219')) AND .GAMMA.1 HEAVY CHAIN ANTI-CD20 (1-452) (HUMANIZED VH (HOMO SAPIENS IGHV3-23*04 (82%) (IGHD)-IGHJ4*01 (93%)) (8.8.15) (1-122) -HOMO SAPIENS IGHG1*03 (CH1(R97>K(219),), CH2(N67>G(302)), CH3(T26>W(371))) (123-452)) (225-213')-DISULFIDE WITH KAPPA LIGHT CHAIN ANTI-CD20 (1'-213') (HUMANIZED V-KAPPA (HOMO SAPIENS IGKV1-39*01 (87%) IGKJ1*01) (5.3.9) (1'-106') -HOMO SAPIENS IGKC*01 (107-213')), HETERODIMER (228-231'':231-234'')-BISDISULFIDE
LUNSUMIO
MOSUNETUZUMAB [INN]
MOSUNETUZUMAB [USAN]
MOSUNETUZUMAB [WHO-DD]
MOSUNETUZUMAB-AXGB
RG7828
RG-7828
RG-7828 (ANTI-CD20 & CD3)
RO7030816
RO-7030816

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

MOSUNETUZUMAB

Synonyms and Mappings

Resources